KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Current Leases (2019 - 2025)

Inovio Pharmaceuticals' Current Leases history spans 7 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Current Leases rose 12.93% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, up 12.93%, while the annual FY2024 figure was $2.5 million, 3.77% up from the prior year.
  • Current Leases for Q3 2025 was $2.7 million at Inovio Pharmaceuticals, up from $2.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.8 million in Q3 2022 and bottomed at $2.1 million in Q3 2023.
  • The 5-year median for Current Leases is $2.5 million (2021), against an average of $2.5 million.
  • The largest annual shift saw Current Leases decreased 24.92% in 2023 before it grew 19.5% in 2025.
  • A 5-year view of Current Leases shows it stood at $2.6 million in 2021, then rose by 7.68% to $2.8 million in 2022, then dropped by 14.17% to $2.4 million in 2023, then increased by 3.77% to $2.5 million in 2024, then rose by 9.66% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Current Leases are $2.7 million (Q3 2025), $2.7 million (Q2 2025), and $2.6 million (Q1 2025).